Treatment Information

Back

Colon Cancer treatment details. Biologic therapy.

University of Chicago, Chicago, IL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chicago, IL
Treatments:Biologic therapyHospital:University of Chicago
Drugs:Journal:Link
Date:May 2011

Description:

Patients:
This phase II study involved 19 patients with previously treated metastatic colorectal cancer. The median patient age was 64 years and 58% were male.

Treatment:
Patients were treated with the biologic therapy agent called dasatinib, which is an inhibitor of protein-tyrosine kinases, and therefore interferes with internal signals in cancer cells.

Toxicities:
Treatment-related death due to heart attack was reported for this study. Grade 3 fatigue, anemia, anorexia, and nausea/vomiting were also reported.

Results:
The reported median overall survival was 5.1 months.

Correspondence: Dr. Hedy L. Kindler; email: [email protected]



Back